arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Rein Therapeutics, Inc.

RNTX
$0.82 ▲ +0.04 (+5.42%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
42 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
10
Health
Poor
Bearish
auto_awesome

Analytical Summary

Rein Therapeutics, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $24.9M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -35.6%
FCF / Share $-0.11
Trailing P/E
Price / Book 2.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

42-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-5.84M
↓ -6.1%
FCF / Share Free cash flow per share
$-0.11
↑ +60.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
0
Cash Quality
35

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 42 quarters